Back to search page

rdit20170529009

Research grant - Looking for pharmaceutical companies developing drugs for neurodegenerative and mental disorders or companies involved in the development of new strategies for neuroprotection

RESEARCH PROFILE   REQUEST   ADD TO FAVOURITES
PRINT

 

ABSTRACT

An Italian research group has developed a platform to screen compounds for the treatment of neurodegenerative and mental disorders. They are looking for pharmaceutical companies developing drugs for neurodegenerative and mental disorders or companies involved in the development of new strategies for neuroprotection. A regional grant can support the co-development of the research results by paying the costs of one year research fellowship.


FULL DESCRIPTION

An Italian research group has developed a platform to screen compounds for the treatment of neurodegenerative and mental disorders. The platform developed is a high-throughput cell-based assay which allows the detection of natural or synthetic compounds able to activate translation of the different Brain-Derived Neurotrophic Factor (BDNF) transcripts. BDNF is a potent growth and trophic factor of the family of secretory proteins called neurotrophins, and promotes the survival and maturation of various cell types in the brain. Thus, increased production of BDNF can be a therapeutic strategy for neurological diseases. In addition, BDNF stimulates tissue regeneration of periodontal tissue, skin, gut and muscle. The platform, through the great expertise of the researchers about the mechanisms controlling BDNF translation, provides a technology for quantitative BDNF protein production, processing and purification. They also offer validated in vitro and in vivo assays to test BDNF and drug-induced BDNF effects.

The research group has a longstanding expertise in research projects.

They are looking for pharmaceutical companies developing drugs for neurodegenerative and mental disorders or companies involved in the development of new strategies for neuroprotection. The role of the company will be the co-development of the research results (the costs of one year fellowship grant will be payed by the project).

Deadline of the call: 30/08/2017
Deadline for EoIs: 15/07/2017


Partner expertise sought:

- Specific area of activity of the partner: Type: pharmaceutical companies developing drugs for neurodegenerative and mental disorders or companies involved in the development of new strategies for neuroprotection.
Role: co-development of the research results.


Advantages & innovations:

The platform allows identifying compounds that selectively activate translation of the different BDNF transcripts. The test system is very sensitive and flexible (96/384/1536-well plates) for the use in a large variety of eukaryotic cell types. It is time saving because allows one-shot experiment for multiple BDNF variants in high-throughput. Moreover it is robustly quantitative because based on a luminescent technology with high dynamic range of responsiveness.


IPR:

Patents granted

Sign-in or create an account

To express an interest in this profile, you must first sign in or create a new account.

If you already have an account, sign in here

Not got an account yet, sign up here

KEY INFORMATION

Country of origin
ITALY
Profile date
26/06/2017
Deadline
26/06/2018

PARTNERSHIP(S) SOUGHT

Research cooperation agreement

CLASSIFICATIONS

INDUSTRY SECTORS
Life Sciences \ Biosciences and Health \ Engineering \ Drug Discovery and Drug Development \ Diagnostics \ Medical Devices
TECHNOLOGY KEYWORDS
BIOLOGICAL SCIENCES / Medicine, Human Health / Neurology, Brain Research / BIOLOGICAL SCIENCES / Medicine, Human Health / Pharmaceutical Products / Drugs
COMMERCIAL KEYWORDS
Research and experimental development on biotechnology
MARKET KEYWORDS
MEDICAL/HEALTH RELATED / Therapeutic / Therapeutic services / MEDICAL/HEALTH RELATED / Other Medical/Health Related / Pharmaceuticals/fine chemicals

FIND OUT MORE

Contact Enterprise Europe Network Scotland by email at info@enterprise-europe-scotland.com, quoting reference number rdit20170529009